Orion Oyj (OTCMKTS:ORINY) Trading Down 0.9% – Here’s What Happened

Orion Oyj (OTCMKTS:ORINY)’s share price dropped 0.9% during mid-day trading on Tuesday . The stock traded as low as $23.36 and last traded at $23.36. Approximately 151 shares were traded during trading, a decline of 69% from the average daily volume of 488 shares. The stock had previously closed at $23.57.

Orion Oyj Trading Down 0.9 %

The company has a debt-to-equity ratio of 0.31, a current ratio of 2.39 and a quick ratio of 1.29. The company’s fifty day moving average is $25.57 and its 200-day moving average is $23.63. The stock has a market cap of $6.59 billion, a PE ratio of 18.54 and a beta of 0.22.

Orion Oyj (OTCMKTS:ORINY) last issued its earnings results on Tuesday, October 29th. The company reported $0.63 earnings per share (EPS) for the quarter. Orion Oyj had a net margin of 23.01% and a return on equity of 41.41%. The firm had revenue of $517.97 million during the quarter. On average, analysts predict that Orion Oyj will post 1.26 earnings per share for the current fiscal year.

Orion Oyj Cuts Dividend

The company also recently disclosed a dividend, which was paid on Thursday, November 7th. Shareholders of record on Wednesday, October 16th were issued a $0.2405 dividend. The ex-dividend date of this dividend was Wednesday, October 16th. Orion Oyj’s payout ratio is 26.19%.

Orion Oyj Company Profile

Orion Oyj develops, manufactures, and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients (APIs) in Finland, Scandinavia, rest of Europe, North America, and internationally. The company provides prescription drugs and self-care products, which includes Nubeqa for the treatment of prostate cancer; Precedex, Dexdor, and Precedex for human use; Burana for inflammatory pain; Divina series for menopausal symptoms; Trexan for rheumatoid arthritis and cancer; Stalevo, Entacapone, and Comtess/Comtan for Parkinson’s disease; Biosimilars for rheumatoid arthritis and inflammatory bowel diseases; and Simdax for acute decompensated heart failure, as well as Fareston for breast cancer.